Get the Stockscreener App
11.26
5.22%
-0.62
After Hours:
11.39
0.13
+1.15%
Nurix Therapeutics Inc stock is traded at $11.26, with a volume of 1.24M.
It is down -5.22% in the last 24 hours and down -1.14% over the past month.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
See More
Previous Close:
$11.88
Open:
$11.55
24h Volume:
1.24M
Relative Volume:
1.46
Market Cap:
$860.82M
Revenue:
$54.55M
Net Income/Loss:
$-193.57M
P/E Ratio:
-3.8962
EPS:
-2.89
Net Cash Flow:
$-181.86M
1W Performance:
-2.34%
1M Performance:
-1.14%
6M Performance:
-42.87%
1Y Performance:
-48.54%
1-Day Range:
$11.06
$11.67
1-Week Range:
$11.06
$12.33
52-Week Range:
$8.18
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics Inc
Sector
Industry
Phone
(415) 660-5320
Address
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Compare NRIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
11.26 | 908.22M | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | Leerink Partners | Market Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | Jefferies | Buy |
| Sep-06-24 | Resumed | Robert W. Baird | Outperform |
| Jul-31-24 | Initiated | Truist | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-09-23 | Initiated | Barclays | Overweight |
| Feb-28-23 | Initiated | Oppenheimer | Outperform |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Dec-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-30-21 | Resumed | Piper Sandler | Overweight |
| Apr-30-21 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Nov-19-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Stifel | Buy |
View All
Nurix Therapeutics Inc Stock (NRIX) Latest News
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Gwenn Hansen Sells 4,308 Shares - MarketBeat
What are Nurix Therapeutics Inc. company’s key revenue driversPost Market Recommendation For 2025 - jammulinksnews.com
Is it the right time to buy Nurix Therapeutics Inc. stockMarket Forecast Insights For 2025 - jammulinksnews.com
Why is Nurix Therapeutics Inc. stock attracting strong analyst attentionPre Market Review For Consistent Profits - jammulinksnews.com
How many analysts rate Nurix Therapeutics Inc. as a “Buy”Swing Trade Report To Watch Now - jammulinksnews.com
ARK Investment Management LLC Has $18.90 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics’ ring sells $46k in stock to cover tax obligations - Investing.com India
Nurix therapeutics (NRIX) CSO Hansen sells $51k in stock By Investing.com - Investing.com Nigeria
Nurix Therapeutics CFO van Houte sells $51,695 in shares By Investing.com - Investing.com India
Nurix therapeutics (NRIX) CSO Hansen sells $51k in stock - Investing.com
Nurix Therapeutics CFO van Houte sells $51,695 in shares - Investing.com
Nikko Asset Management Americas Inc. Sells 33,252 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Will Nurix Therapeutics Inc. Hold Gains Into CloseMulti-Bagger Potential Stock Forecast Tools Released - metal.it
Nurix Therapeutics (NASDAQ:NRIX) Trading Up 4.9%Still a Buy? - MarketBeat
Does Nurix Therapeutics Inc. stock pay reliable dividendsAI Trading Suggestions With Accuracy Focus Released - metal.it
Y Intercept Hong Kong Ltd Invests $374,000 in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
New York State Common Retirement Fund Boosts Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingTrade Insight With Community Collaboration Supported - metal.it
Does Nurix Therapeutics Inc. stock perform well during market downturnsFree Stock Selection - jammulinksnews.com
What makes Nurix Therapeutics Inc. stock price move sharplyGet insider insights into market trends - jammulinksnews.com
How does Nurix Therapeutics Inc. generate profit in a changing economyAccelerated investment success - jammulinksnews.com
Massachusetts Financial Services Co. MA Has $511,000 Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
What drives Nurix Therapeutics Inc. stock priceTremendous financial leverage - PrintWeekIndia
Nurix Therapeutics Inc. Stock Analysis and ForecastPhenomenal returns - PrintWeekIndia
Non-Hodgkin’s Lymphoma Market Forecast to Surge with Growing Adoption of Targeted and Cell-Based Therapies | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $34 - 富途牛牛
Is Nurix Therapeutics Inc. a good long term investmentExceptional trading results - Autocar Professional
Hussman Strategic Advisors Inc. Takes Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Down 5.4%What's Next? - MarketBeat
Janux Therapeutics Receives Buy Rating from Leerink Partners Amid Strategic Initiatives and Long-Term Growth Potential - AInvest
What analysts say about Nurix Therapeutics Inc. stockUnmatched profit potential - jammulinksnews.com
Q3 EPS Forecast for Nurix Therapeutics Raised by Analyst - MarketBeat
Janux Therapeutics (JANX) Soars 2.31% on R&D Day Announcement - AInvest
Nurix Therapeutics Inc Stock (NRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):